巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Precigen

    PGEN
    2.425
    0.110
    4.53%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Precigen - 延遲價格・最後更新於 10/08 2:46
    最高位
    2.440
    最低位
    2.200
    開市價
    --
    前收市價
    2.320
    成交量(千)
    55.46
    成交額(百萬)
    0.99
    買入
    2.420
    賣出
    2.430
    每手股數
    --
    市值(百萬)
    503.66
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    6.455 - 1.120
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Precigen
    證券代碼
    PGEN.US
    所屬板塊
    Biotechnology
    公司業務
    Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
    發行量
    206931842
    公司總部
    20374 Seneca Meadows Parkway
    公司網址
    http://www.precigen.com
    公司電郵
    investors@precigen.com
    公司電話
    +1 301 556-9900
    暫無內容

    關於

    Precigen(PGEN.US)所屬的行業板塊為Biotechnology。
    Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
    詳細公司背景可參考: http://www.precigen.com